Literature DB >> 17806136

Rosiglitazone and cardiovascular risk.

Edoardo Mannucci, Matteo Monami, Niccolò Marchionni.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17806136

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Clinical features of pediatric nonalcoholic fatty liver disease: a need for increased awareness and a consensus for screening.

Authors:  Jeremy P Middleton; R Constance Wiener; Barrett H Barnes; Matthew J Gurka; Mark D DeBoer
Journal:  Clin Pediatr (Phila)       Date:  2014-01-28       Impact factor: 1.168

Review 2.  Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?

Authors:  Edoardo Mannucci; Matteo Monami
Journal:  Curr Diab Rep       Date:  2009-10       Impact factor: 4.810

3.  Glucagon-like peptide-1 receptor agonists and cardiovascular events: a meta-analysis of randomized clinical trials.

Authors:  Matteo Monami; Francesco Cremasco; Caterina Lamanna; Claudia Colombi; Carla Maria Desideri; Iacopo Iacomelli; Niccolò Marchionni; Edoardo Mannucci
Journal:  Exp Diabetes Res       Date:  2011-04-26

4.  Updating insights into rosiglitazone and cardiovascular risk through shared data: individual patient and summary level meta-analyses.

Authors:  Joshua D Wallach; Kun Wang; Audrey D Zhang; Deanna Cheng; Holly K Grossetta Nardini; Haiqun Lin; Michael B Bracken; Mayur Desai; Harlan M Krumholz; Joseph S Ross
Journal:  BMJ       Date:  2020-02-05

5.  Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials.

Authors:  Matteo Monami; Caterina Lamanna; Niccolò Marchionni; Edoardo Mannucci
Journal:  Diabetes Care       Date:  2008-03-28       Impact factor: 19.112

Review 6.  Continued efforts to translate diabetes cardiovascular outcome trials into clinical practice.

Authors:  Angelo Avogaro; Gian Paolo Fadini; Giorgio Sesti; Enzo Bonora; Stefano Del Prato
Journal:  Cardiovasc Diabetol       Date:  2016-08-11       Impact factor: 9.951

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.